Skip to main content

and
  1. Article

    Open Access

    Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

    Patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplantation (ASCT) have lower survival rates and may benefit from frontline regimens that include novel agents. Thi...

    Enrique M. Ocio, Aurore Perrot, Pierre Bories, Jesus F. San-Miguel in Leukemia (2023)

  2. No Access

    Article

    Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant

    Luisa Giaccone, Lucia Brunello, Jaime Suarez Londono in Bone Marrow Transplantation (2022)

  3. Article

    Open Access

    Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

    Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased ris...

    Heinz Ludwig, Mario Boccadoro, Philippe Moreau, Jesus San-Miguel, Michele Cavo in Leukemia (2021)

  4. No Access

    Article

    Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study

    Sara Bringhen, Roberto Mina, Anna Maria Cafro, Anna Marina Liberati in Leukemia (2018)

  5. No Access

    Article

    Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

    Multiple myeloma is a disease typical of the elderly, and, because of the increase in life expectancy of the general population, its incidence is expected to grow in the future. Elderly patients represent a pa...

    Alessandra Larocca, Sandra Maria Dold, Sonja Zweegman, Evangelos Terpos in Leukemia (2018)